Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547 59. 279. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309 21. 280. Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intol- erant to angiotensin-converting enzyme inhibitors: a randomised con- trolled trial. Lancet. 2008;372:1174 83. 281. Dagenais GR, Pogue J, Fox K, et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet. 2006;368:581 8. 282. Danchin N, Cucherat M, Thuillez C, et al. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long- term randomized controlled trials. Arch Intern Med. 2006;166:787 96. 283. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation. 1998;97:2202 12. 284. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 Amsterdam et al 2014 AHA/ACC NSTE-ACS Guideline e401 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet. 1995;345:669 85. 285. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortal- ity and morbidity in patients with left ventricular dysfunction after myo- cardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669 77. 286. Kaul P, Ezekowitz JA,Armstrong PW, et al. Incidence of heart failure and mortality after acute coronary syndromes.Am Heart J. 2013;165:379 85. 287. 